全文获取类型
收费全文 | 106篇 |
免费 | 5篇 |
专业分类
耳鼻咽喉 | 1篇 |
基础医学 | 22篇 |
临床医学 | 6篇 |
内科学 | 26篇 |
皮肤病学 | 4篇 |
神经病学 | 2篇 |
特种医学 | 6篇 |
外科学 | 15篇 |
预防医学 | 2篇 |
眼科学 | 1篇 |
药学 | 16篇 |
肿瘤学 | 10篇 |
出版年
2023年 | 1篇 |
2022年 | 3篇 |
2021年 | 6篇 |
2020年 | 3篇 |
2019年 | 8篇 |
2018年 | 5篇 |
2017年 | 2篇 |
2016年 | 5篇 |
2015年 | 2篇 |
2014年 | 9篇 |
2013年 | 5篇 |
2012年 | 7篇 |
2011年 | 6篇 |
2010年 | 3篇 |
2009年 | 3篇 |
2008年 | 4篇 |
2007年 | 8篇 |
2006年 | 3篇 |
2005年 | 10篇 |
2004年 | 6篇 |
2003年 | 7篇 |
2002年 | 2篇 |
2001年 | 2篇 |
2000年 | 1篇 |
排序方式: 共有111条查询结果,搜索用时 31 毫秒
1.
2.
Santosh L. Saraf Annie L. Oh Pritesh R. Patel Karen Sweiss Matthew Koshy Sally Campbell-Lee Michel Gowhari Shivi Jain David Peace John G. Quigley Irum Khan Robert E. Molokie Nadim Mahmud Victor R. Gordeuk Damiano Rondelli 《Biology of blood and marrow transplantation》2018,24(8):1759-1765
We report on the screening and development of haploidentical hematopoietic stem cell transplantation (HSCT) for adult patients with clinically aggressive sickle cell disease (SCD) at our institution. Of 50 adult SCD patients referred for HSCT between January 2014 and March 2017, 20% were denied by insurance. Of 41 patients initially screened, 10% lacked an available haploidentical donor, 29% had elevated donor-specific antibodies (DSAs), and 34% declined to proceed to HSCT. All 10 patients who were transplanted received peripheral blood stem cells. The initial 2 were conditioned with alemtuzumab/total body irradiation (TBI) 3?Gy followed by post-transplant cyclophosphamide and failed to engraft. The next 8 patients received the regimen developed at Johns Hopkins University with TBI 3?Gy. Granulocyte colony-stimulating factor was administered from day +12 in those with HbS < 30%. All 8 patients engrafted with a median time to neutrophil >.5 × 109/L of 22 days (range, 18 to 23). One patient subsequently lost the graft, and 7 (87.5%) maintained >95% donor cell chimerism at 1-year post-HSCT. Two patients developed acute graft-versus-host disease (GVHD) of at least grade II. One had chronic GVHD and died >1 year after HSCT of unknown causes. With a median follow-up of 16 months (range, 11 to 29), 7 patients (87.5%) are alive. Our findings suggest that limited insurance coverage, high rate of DSAs, and patient declining HSCT may limit the availability of haploidentical HSCT in adult SCD patients. The modified Hopkins regimen used here demonstrates high engraftment and low morbidity rates and should be tested in larger, multicenter, prospective clinical trials. 相似文献
3.
Ebrahimzadeh Seyed Amir Manzoor Komal Edlow Jonathan A. Selim Magdy Chang Yu-Ming Bhadelia Rafeeque A. Mehta Pritesh 《Emergency radiology》2022,29(5):825-832
Emergency Radiology - Computed tomography angiographies are frequently performed in the emergency department (ED) for the assessment of cervical artery dissection (CeAD) due to the high risk of... 相似文献
4.
5.
6.
Sonia Christian Saad Arain Pritesh Patel Irum Khan Gregory S. Calip Vaibhav Agrawal Karen Sweiss Shawn Griffin Kirk Cahill Heiko Konig Aysenur Esen Ardaman Shergill Olatoyosi Odenike Wendy Stock John G. Quigley 《American journal of hematology》2020,95(8):937-943
Relapsed or refractory acute myeloid leukemia (R/R AML) has a poor prognosis and is best treated with salvage chemotherapy as a bridge to allogeneic stem cell transplant (alloSCT). However, the optimal salvage therapy remains unknown. Here we compared two salvage regimens; mitoxantrone, etoposide, and cytarabine (MEC) and mitoxantrone and high-dose Ara-C (Ara-C couplets). We analyzed 155 patients treated at three academic institutions between 1998 and 2017; 87 patients received MEC and 68 received Ara-C couplets. The primary endpoint was overall response (OR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), duration of hospitalization, hematologic and nonhematologic toxicities, and success in proceeding to alloSCT. Baseline characteristics of the cohorts were well matched, though patients receiving Ara-C couplets had more co-morbidities (48.5% vs 33%; P = .07). OR was achieved in 43.7% of MEC and 54.4% of Ara-C couplets patients (P = .10). Ara-C couplets patients also trended towards a longer OS and PFS, more frequently proceeded to alloSCT (31% vs 54.4%; P = .003), and experienced less febrile neutropenia (94% vs 72%; P < .001) and grade 3/4 gastrointestinal toxicities (17.2% vs 2.94%; P = .005). No significant differences in other toxicities or median duration of hospitalization were noted. This is the first multi-institutional study directly comparing these regimens in a racially diverse population of R/R AML patients. Although these regimens have equivalent efficacy in terms of achieving OR, Ara-C couplets use is associated with significant reductions in toxicities, suggesting it should be used more frequently in these patients. 相似文献
7.
Aharon Frimerman M.D. Eitan Abergel M.D. David S. Blondheim M.D. Avraham Shotan M.D. Simcha Meisel M.D. M.Sc. Michael Shochat M.D. Pritesh Punjabi M.D. Ariel Roguin M.D. Ph.D. 《Journal of interventional cardiology》2016,29(2):225-231
Objectives
We present our experience with a novel method for real time co‐registration of intravascular ultrasound (IVUS) and coronary angiography.Background
A major limitation of the current practice of concomitant use of coronary angiography and IVUS is that the locations of the acquired IVUS images are not correlated with their exact locations on the vessel roadmap obtained by coronary angiography.Methods
Phantoms simulating the coronary tree were used to test the accuracy and potential of co‐registration. Subsequently we examined patients who underwent IVUS during cardiac catheterization. Analysis and feasibility were performed in 42 arteries of 36 patients.Results
The statistical validation in phantoms resulted in a co‐registration accuracy of 1.12 mm. The length measurement on an angiogram resulted in an accuracy of 0.38 mm. Co‐registration in patients was successful in all cases and four categories were assisted by 1(bad) to 5 (good) grading. Accuracy (the co‐registration precision in pointing at the exact corresponding location): 4.8±0.41; Ease of use and workflow: 4.74±0.44; Stent landing zone detection and evaluation: 4.58±0.5; Stent landing zone length and diameter measurement: 4.94±0.23. The co‐registration error was estimated as no more than 1 mm.Conclusion
In this pilot study, we found that the novel IVUS and coronary angiography co‐registration method is accurate, easy to use, fast and user‐friendly. This method precludes the need to use motorized automated pull back device. (J Interven Cardiol 2016;29:225–231)8.
Elisabetta Prina Pritesh Mistry Laura E. Sidney Jing Yang Ricky D. Wildman Marina Bertolin Claudia Breda Barbara Ferrari Vanessa Barbaro Andrew Hopkinson Harminder S. Dua Stefano Ferrari Felicity R. A. J. Rose 《Stem cell reviews》2017,13(3):430-441
In recent years, there has been increased research interest in generating corneal substitutes, either for use in the clinic or as in vitro corneal models. The advancement of 3D microfabrication technologies has allowed the reconstruction of the native microarchitecture that controls epithelial cell adhesion, migration and differentiation. In addition, such technology has allowed the inclusion of a dynamic fluid flow that better mimics the physiology of the native cornea. We review the latest innovative products in development in this field, from 3D microfabricated hydrogels to microfluidic devices. 相似文献
9.
Aspirin Resistance and Genetic Polymorphisms 总被引:16,自引:0,他引:16
Differences in genetic makeup or polymorphisms can affect individual drug response. Detecting genetic variation may help predict how a patient will respond to a drug and could be used as a tool to select optimal therapy, tailor dosage regimens, and improve clinical outcomes. The data are replete relative to the therapeutic efficacy of aspirin (ASA) for the prevention of ischemic events. However, there is a paucity of published data on the relationship between polymorphisms and the clinical effects on ASA. Prothrombotic genetic variations that may contribute to ASA resistance, and increased risk of cardiovascular events may involve: (1) a polymorphism on the cyclooxygenase-1 (COX-1) gene affecting Ser529; (2) overexpression of COX-2 mRNA on platelets and endothelial cells; (3) polymorphism PLA1/A2 of the gene encoding glycoprotein IIIa (GPIIIa); and (4) the homozygous 807T (873A) polymorphism allied with increased density of platelet GP Ia/IIa collagen-receptor gene. Because of the possible increased risk of ischemic vascular events, carriers of these genetic polymorphisms may be resistant to the antithrombotic effects of ASA and should be considered for additional or alternative treatment. 相似文献
10.